FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)

FlipGFP assay characterizes the intracellular drug target engagement to M(pro) and PL(pro) and can be performed in the biosafety level 1/2 settings. Here, we provide the detailed protocol for the cell-based FlipGFP assay to identify and characterize SARS-CoV-2 M(pro) and PL(pro) inhibitors. We descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Haozhou, Hu, Yanmei, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156985/
https://www.ncbi.nlm.nih.gov/pubmed/37329507
http://dx.doi.org/10.1016/j.xpro.2023.102323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156985/
https://www.ncbi.nlm.nih.gov/pubmed/37329507
http://dx.doi.org/10.1016/j.xpro.2023.102323

Ejemplares similares